In this context, Weigert O et al. (2012) demonstrated that the HSP90 inhibitor NVP_AUY922 promotes the degradation of both wild-type and mutant JAK2, improves survival in murine models of human and mice CRLF2-rearranged B-ALL, and reduces the proliferation of BaF3 CRLF2-positive cells harboring kinase domain point mutations. This evidence concerns the gene JAK2 and precursor B-cell acute lymphoblastic leukemia.